Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496531 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TDP1 | |
| SCHEMBL4180706 | 0.84 | PGD (0.33) | TDP1 | |
| SCHEMBL4180699 | 0.84 | PGD (0.33) | TDP1 | |
| SCHEMBL4455207 | 0.84 | PGD (0.33) | TDP1 | |
| SCHEMBL4702274 | 0.82 | — | — | |
| SCHEMBL9805186 | 0.82 | — | — | |
| SCHEMBL21234118 | 0.82 | — | — | |
| SCHEMBL25184696 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9622524 | 0.81 | — | — | |
| SCHEMBL2386145 | 0.81 | TSHR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598393-B2 | Structural variants of mycolactones for use in modulating inflammation, immunity and pain | INSTITUT PASTEUR (FR) | 2017-03-21 | — | — | US | disclosed |
| US-20140329771-A1 | STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN | INSTITUT PASTEUR (FR) | 2014-11-06 | — | — | US | disclosed |
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329771-A1 | STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN | IL1B, MYC, IL1A | ALDH1A1 2781/4885TDP1 3921/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | ALDH1A1 1851/4885TDP1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.